<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461953</url>
  </required_header>
  <id_info>
    <org_study_id>2014-011</org_study_id>
    <nct_id>NCT02461953</nct_id>
  </id_info>
  <brief_title>Combination of Hemodialysis With Hemoperfusion：A Clinical Study</brief_title>
  <official_title>HA130 Hemoperfusion Apparatus Combined Hemodialysis to Improve Quality of Life in Patients Undergoing Maintenance Hemodialysis：A Perspective, Randomized, Controlled Multicenter Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, controlled multicenter clinical study. The aim of&#xD;
      the study is to investigate whether the combination of maintenance hemodialysis (MHD) with&#xD;
      hemoperfusion (HP) could improve the clearance rate of middle and large molecule uremic&#xD;
      toxins so as to improve the quality of life of MHD patients and reduce their mortality rate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance rate of uremic toxins</measure>
    <time_frame>0,3,6,12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life</measure>
    <time_frame>0,3,6,12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">440</enrollment>
  <condition>Renal Dialysis</condition>
  <condition>Hemoperfusion</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>low flux hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low flux hemodialysis alone, 3 times a week, 4 hours per session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high flux hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high flux hemodialysis alone, 3 times a week, 4 hours per session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low flux hemodialysis + hemoperfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low flux hemodialysis 2times a week and the HD+HP once a week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high flux hemodialysis + hemoperfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high flux hemodialysis 2times a week and the HD+HP once a week</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hemoperfusion apparatus</intervention_name>
    <arm_group_label>high flux hemodialysis + hemoperfusion</arm_group_label>
    <arm_group_label>low flux hemodialysis + hemoperfusion</arm_group_label>
    <other_name>hemoperfusion apparatus(HA-130;Jafron Biomedical Co., Ltd）</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>low flux dialyzer</intervention_name>
    <arm_group_label>low flux hemodialysis</arm_group_label>
    <arm_group_label>low flux hemodialysis + hemoperfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>high flux dialyzer</intervention_name>
    <arm_group_label>high flux hemodialysis</arm_group_label>
    <arm_group_label>high flux hemodialysis + hemoperfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age≥18, male or female&#xD;
&#xD;
          2. Maintenance hemodialysis duration&gt;3 months&#xD;
&#xD;
          3. Regular hemodialysis,3 times a week,4 hours per session&#xD;
&#xD;
          4. Vascular access unlimited&#xD;
&#xD;
          5. iPTH≥300pg/ml&#xD;
&#xD;
          6. Sign the written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to dialysis equipment&#xD;
&#xD;
          2. PLT&lt;60×10^9/L&#xD;
&#xD;
          3. Blood flow&lt;200ml/min&#xD;
&#xD;
          4. Serum albumin&lt;30g/L&#xD;
&#xD;
          5. Kt/V&lt;1.2&#xD;
&#xD;
          6. iPTH&gt;800pg/ml&#xD;
&#xD;
          7. Hemodiafiltration&#xD;
&#xD;
          8. Coagulation disorder, severe bleeding tendency, with active bleeding&#xD;
&#xD;
          9. Severe hypotension, severe cardiopulmonary insufficiency&#xD;
&#xD;
         10. Under other drug trial&#xD;
&#xD;
         11. Acute infection, severe heart, lung, liver, nervous diseases, malignant tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>June 22, 2018</last_update_submitted>
  <last_update_submitted_qc>June 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Xiangmei Chen</investigator_full_name>
    <investigator_title>Professor,Chief physician,Academician of Chinese Academy of Engineering,Chinese PLA General Hospital</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>hemoperfusion</keyword>
  <keyword>quality of life</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

